| |MAY 20248YOKOGAWA HELPS TO REVOLUTIONIZE THE FIELD OF SINGLE-CELL LIPIDOMICSMANIPAL HOSPITALS ACQUIRES MAJORITY STAKE IN MEDICA SYNERGIEYokogawa Electric Corporation's latest single-cell analysis solution, the Single CellomeTM System SS2000, has been featured in an article published in the high-profile journal Analytical Chemistry regarding groundbreaking work conducted by researchers at the University of Surrey in the emerging field of single-cell lipidomics. The SS2000 is a live cell image device equipped with Yokogawa's original dual-microlens spinning disk imaging technology, and enables cutting-edge life science research.Lipidomics is the large-scale study of lipids, a large family of molecules that play biological roles ranging from maintaining normal operation of the human body to the development of major diseases. Lipidomic studies are conventionally conducted by bulk isolation and analysis of lipids from many cells. While bulk lipid analyses can provide scientists a population average of the lipid profile, they are unable to discern subtle cell-to-cell variations or reveal the spatial or temporal differences to the lipidome caused by cell-cell interactions.Single-cell lipidomics is an emerging field where the lipid composition of single cells is analyzed. These studies help overcome the challenges of bulk lipidomics by offering scientists a means of exploring spatial and temporal differences in addition to intercellular variability. Understanding these differences is key to creating a more complete picture to understand diseases such as cancer. One challenge facing researchers is the ability to isolate single cells in a way that maintains the natural lipidome of a cell. Current methods of single-cell isolation detach and suspend multiple cells at once and then isolate them through a narrow channel, but this can be particularly stressful to cells and may result in alterations to cellular lipid make up. Yokogawa's Single Cellome System SS2000 uses confocal imaging technology to help abrogate challenges with single-cell lipidomics. It is a dual-purpose system that enables live cell imaging and also performs fully automated single-cell and subcellular sampling without going through the suspension process, thereby minimizing stress on the cells. POManipal Hospitals, a leading multispeciality hospital, added that it is gaining an 87 percent stake in Kolkata-based clinic chain Medica Synergie in a contract that industry sources said is expected to be worth an expected 1,400 crore.The acquisition will see the Karnataka-based clinic chain increase its bed count from 9,500 to more than 10,500, making it the biggest healthcare firm in the nation, it said in a proclamation.According to Dilip Jose, MD & CEO, this acquisition also fits Manipal Hospitals' strategy of widening its footprint and presence in Eastern India, including Kolkata, Siliguri, and Ranchi."With this acquisition, Manipal Hospitals builds on its strong presence in Eastern India, enabling us to expand our reach and meet the healthcare needs of this under-served region. We will integrate Medica Synergie into our portfolio and rebrand it," Jose added.Manipal Hospitals, backed by Temasek, a Singapore-based investment firm, anticipates closing the deal after completing a few standard procedures. With the acquisition of Medica, Manipal Emergency Clinics will have 37 clinics spread across 199 urban areas in 14 states.The acquisition marks one more huge speculation by a hospital chain planning to expand its national presence. The hospital chain also announced a similar acquisition of an 84 percent stake in Kolkata-based Emami Group's AMRI Hospitals. PO
< Page 7 | Page 9 >